Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension
Dear member of the investment community
Actelion announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH).
An investor conference call & webcast will be held to discuss the approval at 14:00hrs on 05 January 2016.
|05 January 2016||14:00hrs - 15:00hrs||Basel (CET)|
|13:00hrs - 14:00hrs||UK (GMT)|
|8:00 a.m. - 9:00 a.m.||US (EST)|
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.
|Dial:||Europe:||+41 (0)44 583 18 01|
|UK:||+44 203 194 0561|
|US:||+1 646 722 4897|
Webcast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.
Participant's mode: Listen-Only
The archived Investor Webcast will be available for replay through www.actelion.com approximately 60 minutes after the call has ended.